Burning Rock Dx(US:BNR) Jin Rong Jie·2025-07-31 13:49Group 1 - The stock price of Burning Stone Medical (BNR) opened up by 11.36% on July 31, reaching $6.47 per share, with a total market capitalization of $69.66 million [1] - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Group 2 - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcement [2] - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, holding a leading market share in tumor patient detection in China [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their operations [2] - Burning Stone Medical aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]